Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | DLI following haploHCT PTCy relapse

Christian Chabannon • 30 Mar 2020
Acute Myeloid Leukemia Chronic Myeloid Leukemia General Leukemia Cyclophosphamide

Christian Chabannon, MD, PhD, Paoli-Calmettes Institute, Marseille, France, discusses donor-lymphocyte infusion (DLI) for relapse following haploidentical hematopoietic cell transplantation (haploHCT) with post-transplant cyclophosphamide (PTCy). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Christian Chabannon

1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
2:17
Improving access to advanced therapies: the access to CAR-T in Europe
Christian Chabannon • 17 Feb 2024
1:33
Addressing the changing needs for ad-hoc resources for safe delivery of advanced therapies
Christian Chabannon • 17 Feb 2024
1:36
IFM-2015-03: plerixafor before salvage ASCT in R/R myeloma
Christian Chabannon • 21 Oct 2023

Related Videos

1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals